Biotechnology News

Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline.

Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders  Concurrent $132 million private investment...

Cellution Biologics signs definitive agreement to acquire SimpliDerm®, expanding its allograft portfolio and entering the U.S. breast reconstruction market

Châtillon, France, le 16 juillet 2026 DBV Technologies publie son Rapport Financier Semestriel 2026 ― Modalités de mise à disposition ou de consultation DBV Technologies (Euronext : DBV – ISIN :...

Châtillon, France, July 16, 2026 DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN:...

SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with...

BRISBANE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at...

Châtillon, France, le 16 juillet 2026   DBV Technologies publie ses résultats financiers du 2ème trimestre et 1er semestre 2026 et fait le point sur ses activités Poursuite d’échanges productifs...

Châtillon, France, July 16, 2026 DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update Continued productive engagement with the FDA in support of the BLA...

Industry-wide coverage policy expands reimbursement framework for donor-derived cell-free DNA testingSupports iMDx's commercial strategy in transplant monitoringFinal policy establishes recurring...